在非传染性尿道炎中生物相似因弗利克西马布-Dyyb的有效性
Fatma Zaguia1, Edward L Randerson1, Ramana S Moorthy2
1Uveitis Service, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Ocular immunology and inflammation
|August 15, 2023
概括
生物类似药物infliximab-dyyb有效地治疗非传染性脑膜炎,其复发率较低. 转换为或开始使用因弗利西马布-迪伊布的患者保持了疾病控制.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 非传染性脑膜炎需要有效的长期管理.
- 生物疗法,如infliximab,对于控制炎症性眼病至关重要.
- 生物类药物为原始生物制品提供了潜在的成本效益替代品.
研究的目的:
- 为了评估用生物类似药物infliximab-dyyb.yb治疗的患者内膜炎复发率.
- 评估infliximab-dyyb在维持非传染性脑膜炎疾病控制中的有效性.
主要方法:
- 一个回顾性病例系列审查了14名在2016年至2022年期间接受治疗的非传染性脑膜炎患者.
- 数据包括人口统计,诊断,以前使用因弗利西马布和疾病活性.
- 患者要么从原始因弗力西马布切换,要么直接开始使用因弗力西马布-dyyb.
主要成果:
- 在转换为infliximab-dyyb的8名患者中,没有一个出现复发.
- 在开始接受infliximab-dyyb的6名患者中,有5名患者实现了疾病静止.
- 在原始药物和生物类似药物INFLIXIMAB之间,剂量和施用计划保持一致.
结论:
- 在控制非传染性脑膜炎方面,infliximab-dyyb显示出有效性.
- 生物类似药似乎是维持缓解的可行的治疗选择.
- 进一步的研究可以探索长期结果和比较有效性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153


